PET/CT imaging in cancer: Current applications and future directions

Farwell, Michael D.; Pryma, Daniel A.; Mankoff, David A.

doi:10.1002/cncr.28860

Cited by 196 publications

(128 citation statements)

References 122 publications

(266 reference statements)

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…PET offers whole-body functional imaging and 18 F-2-fluoro-2-deoxy-Dglucose ( 18 F-FDG) PET often in combination with diagnostic CT, is a widely used clinical tool for detection of cancer, staging and assessment of response to therapy [4][5][6]. FDG is a glucose analog, which is transported into cells and trapped as FDG-6-phosphate.…”

Section: Introductionmentioning

confidence: 99%

“…However, the ratio of lactate generation to 18 F-FDG uptake was found to be significantly higher in sarcoma as compared to carcinoma. The results were found both when lactate generation was estimated as an apparent pyruvate-to-lactate rate constant from dynamic 13 C MRS and as an [1][2][3][4][5][6][7][8][9][10][11][12][13] C]lactate to total 13 C ratio from 13 …”

mentioning

confidence: 99%

See 1 more Smart Citation

Combined hyperpolarized 13C-pyruvate MRS and 18F-FDG PET (hyperPET) estimates of glycolysis in canine cancer patients

Hansen

Gutte

Holst

et al. 2018

European Journal of Radiology

View full text Add to dashboard Cite

A B S T R A C TF-FDG uptake were tested within groups. Between groups, the same measures were tested for group differences.Results: The main cancer types of the 17 patients were sarcoma (n = 11), carcinoma (n = 5) and mastocytoma (n = 1). Significant correlations between pyruvate-to-lactate rate constants and 18 F-FDG uptake were found for sarcoma patients, whereas no significant correlations appeared for carcinoma patients. The sarcoma patients showed a non-significant trend towards lower 18 F-FDG uptake and higher lactate generation than carcinoma patients. However, the ratio of lactate generation to 18 F-FDG uptake was found to be significantly higher in sarcoma as compared to carcinoma. The results were found both when lactate generation was estimated as an apparent pyruvate-to-lactate rate constant from dynamic 13 C MRS and as an [1-13 C]lactate to total 13 C ratio from 13 C MRSI. This finding could be important for the interpretation and eventual clinical implementation of hyperpolarized 13 C. In addition, the differences between the two modalities may allow for better metabolic phenotyping performing hybrid imaging in the form of hyperPET. Conclusions

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Combined hyperpolarized 13C-pyruvate MRS and 18F-FDG PET (hyperPET) estimates of glycolysis in canine cancer patients

Hansen

Gutte

Holst

et al. 2018

European Journal of Radiology

View full text Add to dashboard Cite

show abstract

“…Therefore, recurrent tumors need to be detected as soon as possible and treated effectively. Previous studies investigated the utility of FDG-PET in EC (22). PET-CT is widely performed as an imaging examination for the staging and detection of recurrent tumors.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of PET-CT in the Diagnosis and Treatment of Recurrence After Esophageal Cancer Surgery

Kudou

Shiozaki

Fujiwara

et al. 2016

View full text Add to dashboard Cite

Abstract. Aim The present study aimed to retrospectively investigate the utility of positron-emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (PET-CT) in regular followEsophageal cancer (EC) is the eighth most common cancer worldwide, with an estimated 456,000 new cases in 2012 (3.2% of all cases), and the sixth most common cause of death from cancer, with an estimated 400,000 deaths (4.9% of all deaths)(1). Although several diagnostic modalities and multimodal therapies have been developed in recent years, the prognosis of patients with EC remains poor even when curative surgery is performed. Postoperative recurrence occurs in 78% of patients who undergo curative surgery for EC (2, 3). Recurrence of EC is regarded as a grave prognostic sign after curative surgery, with most patients dying due to the progression of their cancer. However, a few patients with postoperative recurrence have achieved long-term survival (4, 5). The development of more effective therapies or examinations is presumed to have improved the clinical outcomes of patients with recurrent EC. In order to achieve further improvements in the prognosis of these patients, the characteristics of recurrent cases that survive long-term, and prognostic factors for recurrent EC need to be elucidated in more detail.Positron-emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose, an analog of glucose, integrated with computed tomography (PET-CT) is a functional imaging technique based on increased glucose uptake and glycolysis by cancer cells. In Japan, EC was approved as an indication for the use of PET-CT under health insurance coverage in April 2006. PET-CT is now widely used and provides a sensitive and specific examination for the staging or diagnosis of recurrent lesions in various lips of cancer (6-8). Furthermore, a previous study showed that PET-CT was useful for the early detection of recurrence after esophagostomy, and contributed to a good prognosis through early detection of single recurrent tumors (5). Although the utility of PET-CT in EC has been reported, an appropriate method for applying PET-CT to follow-up after curative surgery for EC has not yet been established. In order to provide EC patients the best medical care, it is necessary to clarify the utility of PET-CT in postoperative follow-up.PET-CT was implemented at our Institution in March 2007. We have been conducting imaging observations for regular follow-up of patients who underwent curative surgery for EC in our Division using PET-CT since January 2008. The present study aimed to retrospectively investigate the 5473

show abstract

“…In its early years, the prevailing tracers were primarily analogues of biologically active small molecules incorporating a single non-metallic radiolabel. Small-molecule tracers continue to be well represented clinically (SI Table 1 [126][127][128][129] . On the one hand, because of their rapid pharmacokinetic profiles, small-molecule [130][131][132] and many peptide 133 -based tracers are well-suited to procedures involving sequential multiplexing.…”

Section: Combining Data From Different Molecular Contrastsmentioning

confidence: 99%

Multiplexed imaging for diagnosis and therapy

et al. 2017

View full text Add to dashboard Cite

Complex molecular and metabolic phenotypes depict cancers as a constellation of different diseases with common themes. Precision imaging of such phenotypes requires flexible and tuneable modalities capable of identifying phenotypic fingerprints by using a restricted number of parameters whilst ensuring sensitivity to dynamic biological regulation. Common phenotypes can be detected by in vivo imaging technologies, and effectively define the emerging standards for disease classification and patient stratification in radiology. However, for the imaging data to accurately represent a complex fingerprint, the individual imaging parameters need to be measured and analysed in relation to their wider spatial and molecular context. In this respect, targeted palettes of molecular imaging probes facilitate the detection of heterogeneity in oncogene-driven alterations and their response to treatment, and lead to the expansion of rational-design elements for the combination of imaging experiments. In this Review, we evaluate criteria for conducting multiplexed imaging, and discuss its opportunities for improving patient diagnosis and the monitoring of therapy.

show abstract

PET/CT imaging in cancer: Current applications and future directions

Cited by 196 publications

References 122 publications

Combined hyperpolarized 13C-pyruvate MRS and 18F-FDG PET (hyperPET) estimates of glycolysis in canine cancer patients

Combined hyperpolarized 13C-pyruvate MRS and 18F-FDG PET (hyperPET) estimates of glycolysis in canine cancer patients

Efficacy of PET-CT in the Diagnosis and Treatment of Recurrence After Esophageal Cancer Surgery

Multiplexed imaging for diagnosis and therapy

Contact Info

Product

Resources

About